Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Foroni

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Blood|April 17, 2014
The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphomaLucy B Cook, Anat Melamed, Heather Niederer, et al.
Haematologica|November 11, 2003
V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemiaVeronique M Duke, Domenica Gandini, Paul D Sherrington, et al.
British Journal of Haematology|November 9, 2018
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trialGemma M Austin, Katy Knight, Joanne Bell, et al.
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Oncotarget|February 19, 2019
Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?Tamara M H Gall, Gareth Gerrard, Adam E Frampton, et al.
Haematologica|March 30, 2019
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemiaSimone Claudiani, Aoife Gatenby, Richard Szydlo, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemiaForida Y Mortuza, Mary Papaioannou, Ilidia M Moreira, et al.
Leukemia Research|November 3, 2009
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemiaHugues de Lavallade, Pascal Finetti, Nadine Carbuccia, et al.
British Journal of Haematology|December 28, 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemiaSimone Claudiani, Jane F Apperley, Richard Szydlo, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Blood|April 17, 2014
The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphomaLucy B Cook, Anat Melamed, Heather Niederer, et al.
Haematologica|November 11, 2003
V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemiaVeronique M Duke, Domenica Gandini, Paul D Sherrington, et al.
British Journal of Haematology|November 9, 2018
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trialGemma M Austin, Katy Knight, Joanne Bell, et al.
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Oncotarget|February 19, 2019
Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?Tamara M H Gall, Gareth Gerrard, Adam E Frampton, et al.
Haematologica|March 30, 2019
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemiaSimone Claudiani, Aoife Gatenby, Richard Szydlo, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemiaForida Y Mortuza, Mary Papaioannou, Ilidia M Moreira, et al.
Leukemia Research|November 3, 2009
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemiaHugues de Lavallade, Pascal Finetti, Nadine Carbuccia, et al.
British Journal of Haematology|December 28, 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemiaSimone Claudiani, Jane F Apperley, Richard Szydlo, et al.
Pageof 9